Insider Selling: CeriBell (NASDAQ:CBLL) CTO Sells $13,951.95 in Stock

CeriBell, Inc. (NASDAQ:CBLL) CTO Raymond Woo sold 705 shares of the firm’s stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $19.79, for a total transaction of $13,951.95. Following the completion of the transaction, the chief technology officer directly owned 166,912 shares of the company’s stock, valued at $3,303,188.48. This represents a 0.42% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Raymond Woo also recently made the following trade(s):

• On Friday, January 2nd, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $21.18, for a total transaction of $235,352.16.
• On Monday, December 1st, Raymond Woo sold 11,112 shares of CeriBell stock. The shares were sold at an average price of $12.28, for a total value of $136,455.36.

CeriBell Stock Performance

Shares of CeriBell stock opened at $18.67 on Friday. The stock has a market cap of $702.74 million, a PE ratio of -12.70 and a beta of 1.03. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $24.68. The company has a quick ratio of 12.25, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The business has a fifty day simple moving average of $21.11 and a 200-day simple moving average of $16.26.

CeriBell (NASDAQ:CBLL) last announced its quarterly earnings data on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The firm had revenue of $24.78 million during the quarter, compared to the consensus estimate of $23.95 million. On average, sell-side analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Hedge Funds Weigh In On CeriBell

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its position in shares of CeriBell by 11.1% in the third quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company’s stock worth $16,935,000 after buying an additional 147,013 shares during the last quarter. Yu Fan increased its holdings in shares of CeriBell by 10.7% during the 2nd quarter. Yu Fan now owns 1,353,166 shares of the company’s stock valued at $25,345,000 after acquiring an additional 130,964 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of CeriBell by 1,945.9% in the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock valued at $26,797,000 after acquiring an additional 1,162,200 shares in the last quarter. KCM Capital Inc acquired a new stake in CeriBell in the 4th quarter worth approximately $21,930,000. Finally, Novo Holdings A S boosted its position in CeriBell by 2.3% during the second quarter. Novo Holdings A S now owns 900,000 shares of the company’s stock worth $16,857,000 after purchasing an additional 20,000 shares during the period.

Wall Street Analyst Weigh In

CBLL has been the topic of several research reports. BTIG Research reiterated a “buy” rating and issued a $30.00 price objective on shares of CeriBell in a research note on Wednesday, January 28th. Canaccord Genuity Group increased their price objective on CeriBell from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Wednesday, December 17th. JPMorgan Chase & Co. lowered their target price on CeriBell from $21.00 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Finally, TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and a consensus target price of $24.67.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.